HUMIRA and Psoriasis
7 out of 10 adults with moderate to severe plaque Psoriasis on HUMIRA can expect a 75% reduction in skin symptoms (severity and/or extent) after just four months.§
Create Possibilities*
Create Possibilities*
HUMIRA and Psoriasis
7 out of 10 adults with moderate to severe plaque Psoriasis on HUMIRA can expect a 75% reduction in skin symptoms (severity and/or extent) after just four months.§
What is Psoriasis?
Psoriasis is an inflammatory skin condition that causes red, scaly patches of skin.
Find out more about Psoriasis
Find out more
HUMIRA Safety Information
Safety information on this website includes some of the more important information to know about HUMIRA.
How does HUMIRA work?
HUMIRA is a fully human monoclonal antibody. HUMIRA recognises and binds to a specific protein (tumour necrosis factor or TNF-alpha), which is present at increased levels in inflammatory diseases such as Psoriasis.
Taking HUMIRA
What you need to know about taking HUMIRA, including helping you get the best out of your HUMIRA treatment.
Talk with your doctor
Your dermatologist can answer any questions you may have and provide additional information and support.
- NZ-HUM-200021. TAPS BG5630. November 2025.
This site is intended for a New Zealand audience.
Important information about HUMIRA. HUMIRA is a prescription medicine containing adalimumab. HUMIRA is available as a single use pre-filled syringe or single-use pre-filled pen and may contain 20mg, 40mg or 80mg adalimumab. It is used in the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriasis, ulcerative colitis, Crohn’s disease, non-infectious uveitis, and hidradenitis suppurativa. HUMIRA is only used in patients of a specific age group, in diseases of certain severity (e.g. moderate to severe), and/or after some other treatments have been tried (e.g. conventional therapy).
HUMIRA has risks and benefits. Refer to the Safety Information contained on this website for further details. If you have any questions about using HUMIRA, ask your healthcare professional and refer to the Humira Consumer Medicine Information (CMI), the HUMIRA PEN Instructions for Use, the HUMIRA Pre-filled Syringe Instructions for Use or by calling freephone 0800 900 030. Ask your doctor if HUMIRA is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.
HUMIRA is a fully funded medicine under Special Authority for most indications. HUMIRA is not funded for enthesitis-related arthritis, non-radiological axial spondyloarthritis and ulcerative colitis - you will need to pay for this medicine, and any doctor and pharmacy fees that apply.
AbbVie is the company that brings you HUMIRA (adalimumab). For more information about AbbVie, visit www.AbbVie.co.nz.
AbbVie Limited, 6th floor, 156-158 Victoria Street, Wellington, 6011, New Zealand. Ph: 0800 900 030. HUMIRA and Destination You are registered trademarks of AbbVie Biotechnology Ltd.
NZ-HUM-200009. TAPS BG5630. Last updated: November 2025. Copyright © AbbVie Limited.
